Department of Chemical Engineering, Islamic Azad University, Shahrood Branch, Shahrood, Semnan 9WVR+757, Iran.
Frazer Institute, Faculty of Medicine, University of Queensland, Brisbane, Queensland 4102, Australia.
Mol Pharm. 2024 Nov 4;21(11):5373-5391. doi: 10.1021/acs.molpharmaceut.4c00211. Epub 2024 Oct 4.
Transdermal drug delivery systems (TDDS), commonly refered to as "patches", present a nonintrusive technique to provide medication without the need for invasive procedures. These products adhere to the skin and gradually release a specific dosage of medicine at a defined rate into the bloodstream. Compared with other methods of drug delivery, TDDS offer benefits such as reduced invasiveness, convenience for patients, and avoidance of the metabolic processes that occur when drugs are orally consumed. Throughout time, TDDS have been used to provide medications for various medical conditions (such as nicotine, fentanyl, nitroglycerin, and clonidine), and their potential for delivering biologics is currently being explored. This review investigates the current literature on the drug delivery efficacy of medical TDDS through the transdermal route. Additionally, the review addresses potential risks and failure modes associated with TDDS design and development as well as strategies for mitigating such risks. A thorough understanding of failure modes provides a blueprint to mitigate failure and produce high-quality efficacious therapeutics.
经皮给药系统(TDDS),通常被称为“贴片”,提供了一种非侵入性技术,无需进行侵入性手术即可提供药物。这些产品贴附在皮肤上,并以特定的速率逐渐将特定剂量的药物释放到血液中。与其他药物输送方法相比,TDDS 具有减少侵入性、方便患者使用以及避免药物口服时发生的代谢过程等优点。随着时间的推移,TDDS 已被用于提供各种医疗条件(如尼古丁、芬太尼、硝酸甘油和可乐定)的药物治疗,并且目前正在探索其输送生物制剂的潜力。本综述通过经皮途径调查了关于医疗 TDDS 药物输送功效的现有文献。此外,该综述还讨论了与 TDDS 设计和开发相关的潜在风险和故障模式以及减轻这些风险的策略。对故障模式的全面了解为减轻故障和生产高质量有效的治疗方法提供了蓝图。